LexDanaLexDanabeta
Inventor

Paul J. Maddon

Inventor
Scarsdale, NY, US

Overview

49→
Patents
1992–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 49 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides31%
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%
C12NMicroorganisms or enzymes10%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
A01KAnimal husbandry1%
Y02ATechnologies for adaptation to climate change1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
10,500,274Methods for reducing viral load in HIV-1 infected patients20199,695,248'PSMA antibodies and uses thereof'20178,821,877'Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist'20148,470,330'PSMA antibodies and uses thereof'20138,114,965'Compositions of PSMA antibodies'20127,935,797'CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion'20117,901,685'Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion'20117,862,994'Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion'20117,858,298'Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists'20107,850,971'PSMA antibodies and protein multimers'20107,851,600'Anti-CCR5 antibody'20107,736,649'Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors'20107,666,419'Anti-CCR5 antibody'20107,592,014'Stabilized viral envelope proteins and uses thereof'20097,479,553'Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins'20097,446,177'Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection'20087,345,153'Compounds capable of inhibiting HIV-1 infection'20087,138,119'Compositions and methods for inhibition of HIV-1 infection'20067,122,185'Anti-CCR5 antibody'20067,118,859'Methods for inhibiting HIV-1 infection'20067,070,991'Cells expressing a CD4-IgG2 chimeric heterotetramer'20067,060,273'Methods for inhibiting HIV-1 infection'20067,037,497'Methods for inhibiting HIV-1 infection'20067,022,323'Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection'20067,022,324'Stabilized viral envelope proteins and uses thereof'20066,972,126'Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same'20056,737,267'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof'20046,710,173'Stabilized viral envelope proteins and uses thereof'20046,692,745'Compositions and methods for inhibition of HIV-1 infection'20046,673,896'Derivatives of soluble T-4'20046,570,000'DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS'20036,451,313'CD4-gamma2 and CD4-IGG2 chimeras'20026,344,545'Method for preventing HIV-1 infection of CD4 cells'20026,342,586'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof'20026,261,763'Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion'20016,187,748'Uses of CD4-gamma2 and CD4-IgG2 chimeras'20016,177,549'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof'20016,107,019'Method for preventing HIV-1 infection of CD4.sup.+ cells'20006,093,539'DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS'20006,083,478'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof'20006,034,223'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof'20005,958,678'DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS'19995,886,163'HIV-1 antigens, antibody compositions related thereto, and therapeutic and prophylactic uses thereof'19995,871,913'DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS'19995,869,624'HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof'19995,817,767'Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same'19985,422,274'Internal deletion mutants of soluble T4(CD4)'19955,126,433'Soluble forms of the T cell surface protein CD4'19925,110,906'Derivatives of soluble T-4'1992

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1992–2004Patents assigned to UNIV COLUMBIA (8)· patent assignee history
1992–2008Based in New York, NY, US· patent location history
1998–2011Patents assigned to PROGENICS PHARM INC (33)· patent assignee history
2000–2011Based in Elmsford, NY, US· patent location history
2004–2019Based in Scarsdale, NY, US· patent location history
2010–2017Patents assigned to PSMA DEV COMPANY LLC (4)· patent assignee history
2012–2017Patents assigned to MADDON PAUL J (4)· patent assignee history
2012–2017Patents assigned to OLSON WILLIAM C (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
PROGENICS PHARM INC331998–2011
UNIV COLUMBIA81992–2004
MADDON PAUL Jself42012–2017
OLSON WILLIAM C42012–2017
PSMA DEV COMPANY LLC42010–2017
Locations
LocationPatentsSpan
Scarsdale, New York, US212004–2019
New York, New York, US211992–2008
Elmsford, New York, US72000–2011